COMBINATION THERAPIES FOR THE TREATMENT OF CANCER

The present specification relates to the use of an AKT inhibitor, a PI3K-α inhibitor or an mTOR (such as mTORC1) inhibitor in combination with a KDM5C inhibitor to treat cancer, for example breast cancer. Also described is a pharmaceutical composition comprising a compound, a KDM5C inhibitor, and a...

Full description

Saved in:
Bibliographic Details
Main Authors MONTAVA GARRIGA, Lambert, BARRY, Simon Thomas, DUNN, Shanade
Format Patent
LanguageEnglish
French
Published 16.05.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present specification relates to the use of an AKT inhibitor, a PI3K-α inhibitor or an mTOR (such as mTORC1) inhibitor in combination with a KDM5C inhibitor to treat cancer, for example breast cancer. Also described is a pharmaceutical composition comprising a compound, a KDM5C inhibitor, and a pharmaceutically acceptable excipient, where the compound is an AKT inhibitor, a PI3K-α inhibitor or an mTOR inhibitor La présente invention concerne l'utilisation d'un inhibiteur d'AKT, d'un inhibiteur de PI3K-α ou d'un inhibiteur de mTOR (tel que mTORC1) en combinaison avec un inhibiteur de KDM5C pour traiter le cancer, par exemple le cancer du sein. L'invention concerne également une composition pharmaceutique comprenant un composé, un inhibiteur de KDM5C, et un excipient pharmaceutiquement acceptable, le composé étant un inhibiteur d'AKT, un inhibiteur de PI3K-α ou un inhibiteur de mTOR.
Bibliography:Application Number: WO2023EP81387